secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001493152-26-018562
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics gets Nasdaq delisting notice for negative equity of $1.55M
-----------------------------------------------------------------------------

- Negative stockholders' equity of ~$1.55M as of Dec 31, 2025, below Nasdaq's $2.5M minimum requirement.
- Nasdaq letter received April 17, 2026; Company must submit compliance plan by June 1, 2026.
- Raised $6.8M in Q1 2026: $4.6M warrant exercise inducement + $2.25M private placement with existing investor.
- If plan accepted, Nasdaq may grant extension to Oct 14, 2026; failure to regain compliance risks delisting.
- No immediate impact on common stock listing; Company intends to submit plan timely.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226018562/0001493152-26-018562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226018562/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-018562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer